标题
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
作者
关键词
-
出版物
HEPATOLOGY
Volume 62, Issue 5, Pages 1623-1632
出版商
Wiley
发表日期
2015-06-19
DOI
10.1002/hep.27934
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection
- (2014) Karen D. Sims et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2014) Julie A. Lemm et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Update on hepatitis C virus resistance to direct-acting antiviral agents
- (2014) Eva Poveda et al. ANTIVIRAL RESEARCH
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group
- (2014) C Hutchison et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
- (2014) Xavier Forns et al. GASTROENTEROLOGY
- Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus–Induced Membranous Replication Factories, Independent of RNA Replication
- (2014) Carola Berger et al. GASTROENTEROLOGY
- Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
- (2014) David R. McGivern et al. GASTROENTEROLOGY
- JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1
- (2014) HEPATOLOGY RESEARCH
- Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C
- (2014) Jean-Pierre Bronowicki et al. JOURNAL OF HEPATOLOGY
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
- (2014) Ira M Jacobson et al. LANCET
- Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Michael Manns et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Curing Chronic Hepatitis C — The Arc of a Medical Triumph
- (2014) Raymond T. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- In VitroPhenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir
- (2013) Min Jiang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
- (2013) Kelly A. Wong et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
- (2013) Eric Lawitz et al. ANTIVIRAL RESEARCH
- Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
- (2013) James C. Sullivan et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
- (2013) Gregory T. Everson et al. GASTROENTEROLOGY
- NS5A inhibitors in the treatment of hepatitis C
- (2013) Jean-Michel Pawlotsky JOURNAL OF HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy
- (2013) David L. Wyles JOURNAL OF INFECTIOUS DISEASES
- New therapeutic strategies in HCV: polymerase inhibitors
- (2013) Ludmila Gerber et al. LIVER INTERNATIONAL
- HCV direct-acting antiviral agents: the best interferon-free combinations
- (2013) Raymond Schinazi et al. LIVER INTERNATIONAL
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
- (2013) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis
- (2013) Richard J.O. Barnard et al. VIROLOGY
- Antiviral activity and resistance of HCV NS5A replication complex inhibitors
- (2013) Min Gao Current Opinion in Virology
- Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
- (2012) Fiona McPhee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
- (2012) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
- (2012) Christoph Welsch et al. GUT
- A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
- (2012) Eric J. Lawitz et al. JOURNAL OF HEPATOLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
- (2012) Tara L. Kieffer et al. PLoS One
- Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
- (2012) Stefania Paolucci et al. Virology Journal
- The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
- (2012) Keith P. Romano et al. PLoS Pathogens
- Sequence and Phenotypic Analysis for Resistance Monitoring in Hepatitis C Virus Drug Development: Recommendations From the HCV DRAG
- (2011) Ann D. Kwong et al. GASTROENTEROLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
- (2010) R. A. Fridell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
- (2010) O. Lenz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
- (2009) N. J. Liverton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
- (2009) Christoph Sarrazin et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now